RAS Interaction with PI3K: More Than Just Another Effector Pathway
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.
Abstract
RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Oncogenic KRAS signaling also involves PI3K-AKT-mTOR, via the interaction with the catalytic subunits of PI3K (78–80).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Research works printed but not linked: 1
- [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]
Cited by
Items 401–500 of 764
Degen, M., Barron, P., Natarajan, E., Widlund, H. R., & Rheinwald, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078979 · Cited by 16
“The common step could be mitogen binding to and activation of EGFR, which activates the MAPK and PI3K and pathways [50].”
BackgroundInsulin sensitivity in long-lived growth hormone-releasing hormone knockout mice
Zhang, F., Icyuz, M., Liu, Z., Fitch, M. P., & Sun, L. Y. (2020) · Aging · doi:10.18632/aging.103588 · Cited by 13
Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells
Bağca, B. G., Özateş, N. P., Aşık, A., Çağlar, H. O., Gündüz, C., & Avcı, Ç. B. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.058 · Cited by 16
KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics
Tripathi, P. K., Mittal, K. R., Jain, N., Sharma, N., & Jain, C. K. (2023) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666230406085120 · Cited by 18
Dittrich, K., Yıldız-Altay, Ü., Qutab, F., Kwong, D. A., Rao, Z., Nievez-Lozano, S. A., Gardner, H. L., Richmond, J. M., & London, C. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290428 · Cited by 16
“) NRAS, which acts horizontally to and can activate PI3K pathways [21], was significantly upregulated in poor responders (p = 0.”
Background1,8-Dihydroxy-3-methoxy-anthraquinone inhibits tumor angiogenesis through HIF-1α downregulation
Hwang, S. J., Cho, S. H., Bang, H. J., Hong, J.-H., Kim, K. H., & Lee, H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115972 · Cited by 13
Chhichholiya, Y., Singh, H. V., Vashistha, R., Singh, S., & Munshi, A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104250 · Cited by 17
Fomo, K. N., Perumal, N., Manicam, C., Pfeiffer, N., & Grus, F. H. (2024) · Cells · doi:10.3390/cells13090775 · Cited by 13
“This may provide a solid basis for using the neuroretinal R28 cells as a tool to develop new therapeutic approaches for oxidative stress-induced retinal diseases.”
BackgroundKim, R.-K., Suh, Y., Lim, E.-J., Yoo, K.-C., Lee, G.-H., Cui, Y., Son, A.-R., Hwang, E., Uddin, N., Yi, J.-M., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.023 · Cited by 13
Overexpression of wild type or a Q311E mutant MB21D2 promotes a pro‐oncogenic phenotype in HNSCC
Gracilla, D. E., Korla, P. K., Lai, M., Chiang, A., Liou, W., & Sheu, J. J. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12806 · Cited by 13
MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus
Durand, R. E., Reid, J. R., Belasco, J. B., Shellikeri, S., Calle‐Toro, J. S., Cahill, A. M., & Srinivasan, A. S. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.20.24378 · Cited by 13
Angiogenesis regulation by microRNAs and long non-coding RNAs in human breast cancer
Chong, Z. X., Yeap, S. K., & Ho, W. Y. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153326 · Cited by 14
Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice
Kumar, G., Madka, V., Singh, A. K., Farooqui, M., Stratton, N. C., Lightfoot, S. A., Mohammed, A., & Rao, C. V. (2021) · Neoplasia · doi:10.1016/j.neo.2021.05.010 · Cited by 18
Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168)
Dort, M. E. V., Galbán, S., Nino, C. A., Hong, H., Apfelbaum, A. A., Luker, G. D., Thurber, G. M., Atangcho, L., Besirli, C. G., & Ross, B. D. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00111 · Cited by 13
Lin28a overexpression reveals the role of Erk signaling in articular cartilage development
Kobayashi, T., & Kozlova, A. (2018) · Development · doi:10.1242/dev.162594 · Cited by 16
“Ras activation mainly signals through the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K; PIK3R1) pathways (Castellano and Downward, 2011; Papaioannou et al., 2016).”
BackgroundProximal Protein Interaction Landscape of RAS Paralogs
Béganton, B., Coyaud, É., Laurent, E. M. N., Mangé, A., Jacquemetton, J., Romancer, M. L., Raught, B., & Solassol, J. (2020) · Cancers · doi:10.3390/cancers12113326 · Cited by 14
“Over the last years, RAS research has been mainly focused on their pathological roles, whereas little is known about their physiological activities and specificities, although this appears as a prerequisite to clearly discriminate between pathogenic and non-pathogenic behaviors [8,14].”
BackgroundSMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta
Kirchenwitz, M., Stahnke, S., Prettin, S., Borowiak, M., Menke, L., Sieben, C., Birchmeier, C., Rottner, K., Stradal, T. E. B., & Steffen, A. (2022) · Cells · doi:10.3390/cells11101648 · Cited by 16
Cintas, C., Douché, T., Dantes, Z., Mouton‐Barbosa, E., Bousquet, M., Cayron, C., Therville, N., Pont, F., Ramos‐Delgado, F., Guyon, C., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0981 · Cited by 14
Yu, C., Hu, K. M., Nguyen, D., & Wang, Z. A. (2019) · PubMed · Cited by 14
Myosin XVI in the Nervous System
Telek, E., Kengyel, A. M., & Bugyi, B. (2020) · Cells · doi:10.3390/cells9081903 · Cited by 15
“Of note, this mode of activation is reminiscent of the direct recruitment and activation of PI3K by receptor tyrosine kinases [48,49].”
BackgroundIn Vivo Models for Prostate Cancer Research
Adamiecki, R., Hryniewicz‐Jankowska, A., Ortiz, M. A., Li, X., Porter, B. A., Nsouli, I. S., Bratslavsky, G., & Kotula, L. (2022) · Cancers · doi:10.3390/cancers14215321 · Cited by 13
Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer
Jin, L., Jin, M.-H., Nam, A., Park, J.-E., Bang, J., Oh, D., & Bang, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.002 · Cited by 12
Maryam, M., & Idrees, M. (2018) · Journal of Medical Virology · doi:10.1002/jmv.25221 · Cited by 13
Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer
Blas, K. G., Wilson, T. G., Tonlaar, N., Galoforo, S., Hanna, A., Marples, B., & Wilson, G. D. (2018) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2018.04.003 · Cited by 12
Downregulation of miR‑483‑5p inhibits TGF‑β1‑induced EMT by targeting RhoGDI1 in pulmonary fibrosis
Huang, G., Zhang, J., Qing, G., Liu, D., Wang, X., Chen, Y., Wu, Y., Li, Y., & Guo, S. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12177 · Cited by 13
“The PI3K/AKT axis is a key Ras effector (18).”
Dort, M. E. V., Jang, Y., Bonham, C. A., Heist, K., Palagama, D. S. W., McDonald, L., Zhang, E. Z., Chenevert, T. L., Luker, G. D., & Ross, B. D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113996 · Cited by 12
KRASG12R-Independent Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., & Der, C. J. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-94004-1_11 · Cited by 12
Masre, S. F., Rath, N., Olson, M. F., & Greenhalgh, D. A. (2016) · Oncogene · doi:10.1038/onc.2016.402 · Cited by 15
Mohiuddin, M., & Kasahara, K. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20282 · Cited by 12
Reynolds, S. B., Pettit, K. M., Kandarpa, M., Talpaz, M., & Li, Q. (2023) · Cancers · doi:10.3390/cancers15184654 · Cited by 11
“Ras/MAP Kinase pathway signaling is also theorized in various models to be interconnected with a downstream effector PI3K/Akt/mTOR pathway, collectively then enacting various cellular processes that regulate cell growth and survival [81].”
BackgroundRas Protein Activation Is a Key Event in Activity-dependent Survival of Cerebellar Granule Neurons
Xifró, X., Miñano-Molina, A. J., Saura, C. A., & Rodríguez-Álvarez, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.536375 · Cited by 11
The paracrine effects of fibroblasts on Doxorubicin-treated breast cancer cells
Fourie, C., Davis, T., Kriel, J., & Engelbrecht, A. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.05.020 · Cited by 13
Haapalainen, A. M., Daddali, R., Hallman, M., & Rämet, M. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16607 · Cited by 11
FGF8-mediated signaling regulates tooth developmental pace during odontogenesis
Lin, C., Ruan, N., Li, L., Chen, Y., Hu, X., Chen, Y., Hu, X., & Zhang, Y. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.08.009 · Cited by 11
An integrated genetic analysis of epileptogenic brain malformed lesions
Fujita, A., Kato, M., Sugano, H., Iimura, Y., Suzuki, H., Tohyama, J., Fukuda, M., Ito, Y., Baba, S., Okanishi, T., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01532-x · Cited by 12
“MAP2K1 and PTPN11 are essential components of the RAS/MAPK pathway, which partially activates the mTOR pathway by phosphorylating ERK in the RAS/ MAPK pathway and suppressing the TSC2 function [6, 29].”
BackgroundWang, H.-C., Hsu, S., & Lee, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125903 · Cited by 11
Knockdown of ROS1 gene sensitizes breast tumor growth to doxorubicin in a syngeneic mouse model
Tiash, S., Chua, M. J., & Chowdhury, E. H. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3452 · Cited by 11
Su, C., Chen, N.-C., Chyau, C.-C., Tseng, H., & Chou, F. (2018) · Integrative Cancer Therapies · doi:10.1177/1534735418808586 · Cited by 10
“Phosphatidylinositol 3-kinase (PI3K)/AKT is another main effector pathway of Ras, participating in cellular proliferation, transformation, adhesion, apoptosis, survival, and motility.(36) The data demonstrated that IR/MWE downregulated PI3K expression, an observation consistent with the changes in Ras level (Figure 4A…”
ResultHan, Y., Zhang, Y.-Q., Jin, M., Jin, Y.-H., Qiu, M., Li, W.-L., He, C., Yu, L., Hyun, J. W., Lee, J., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.047 · Cited by 12
Holt, J. R., Walter, V., Yin, X., Marron, D. L., Wilkerson, M. D., Choi, H. Y., Zhao, X., Jo, H., Hayes, D. N., & Ko, Y. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0557 · Cited by 13
Zhu, L., Ji, J., Ma, J., Wang, D., Liu, M., Du, J. X., Chen, R., Hou, W., Abbruzzese, J. L., Logsdon, C. D., et al. (2022) · Cancers · doi:10.3390/cancers14112723 · Cited by 12
Villalobos‐Escobedo, J. M., Martínez-Hernández, J. P., Pelagio‐Flores, R., la Rosa, P. M. G. D., Carreras-Villaseñor, N., Abreu‐Goodger, C., & Herrera‐Estrella, A. (2022) · Microbial Genomics · doi:10.1099/mgen.0.000869 · Cited by 13
“It has been reported that PLC and PI3K may regulate cytoskeleton reorganization, cell growth, membrane trafficking and cytokinesis [50].”
Chen, C.-C., Wu, M., Doerksen, R. J., Ho, C., & Huang, T. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.01.048 · Cited by 11
Novkovic, T., Heumann, R., & Manahan‐Vaughan, D. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.052 · Cited by 15
Fernandes, M. S., Melo, S., Velho, S., Carneiro, P., Carneiro, F., & Seruca, R. (2016) · Oncotarget · doi:10.18632/oncotarget.11843 · Cited by 12
“Therefore, our motivation was to overcome this constraint and test the inhibition of PI3K p110α as a therapeutic approach since the activation of this specific isoform has been implicated in CRC progression and KRAS mutants are able to signal through this pathway [4, 29].”
BackgroundLeveraging Genomics for Head and Neck Cancer Treatment
Kemmer, J. D., Johnson, D. E., & Grandis, J. R. (2018) · Journal of Dental Research · doi:10.1177/0022034518756352 · Cited by 13
Molecular Basis of Oncogenic PI3K Proteins
Sheng, Z., Beck, P. J., Gabby, M. E., Habte-Mariam, S., & Mitkos, K. (2024) · Cancers · doi:10.3390/cancers17010077 · Cited by 12
Haeussler, D. J., Pimentel, D. R., Hou, X., Burgoyne, J. R., Cohen, R. A., & Bachschmid, M. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.427765 · Cited by 11
“Thus, activation through Ras occurs by interaction with effector Ras-binding domains (RBDs),(2) such as that found in Raf and the catalytic subunit p110 of phosphatidylinositol 3-kinase (PI3K) (1).”
Regulation of the Small GTPase Ras and Its Relevance to Human Disease
Kulhanek, K. R., Roose, J. P., & Rubio, I. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_2 · Cited by 10
Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein
Janssen, K., Claes, F., Van de Velde, D., Wehbi, V. L., Houben, B., Lampi, Y., Nys, M., Khodaparast, L., Khodaparast, L., Louros, N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214921120 · Cited by 10
“The PI3K-Akt pathway is commonly activated in mutant KRAS-driven tumors, and its inhibition leads to tumor regression (67, 68).”
New insights into RAS in head and neck cancer
Jagadeeshan, S., Novoplansky, O., Cohen, O. M., Kurth, I., Heß, J., Rosenberg, A. J., Grandis, J. R., & Elkabets, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188963 · Cited by 14
Roda, D., Castillo, J., Telechea‐Fernández, M., Gil, A., López‐Rodas, G., Franco, L., González-Rodríguez, P., Roselló, S., Fidalgo, J. A. P., García–Trevijano, E. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130543 · Cited by 11
“The ability of RAS to influence PI3K activity and vice versa has been well documented [28, 29].”
BackgroundGene set-based analysis of mucinous ovarian carcinoma
Chang, C.-M., Wang, P., & Horng, H. (2017) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2016.12.016 · Cited by 11
Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells
Paez, P. A., Kolawole, E. M., Taruselli, M. T., Ajith, S., Dailey, J. M., Kee, S. A., Haque, T. T., Barnstein, B. O., McLeod, J. J. A., Caslin, H. L., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.264234 · Cited by 13
Molecular characteristics of uveal melanoma and intraocular tumors (Review)
Katopodis, P., Khalifa, M. S., & Anikin, V. (2020) · Oncology Letters · doi:10.3892/ol.2020.12270 · Cited by 15
“In the case of PI3K, active Ras directly activates it without an intermediary protein (59).”
BackgroundA Synopsis of Signaling Crosstalk of Pericytes and Endothelial Cells in Salivary Gland
Cucu, I., & Nicolescu, M. I. (2021) · Dentistry Journal · doi:10.3390/dj9120144 · Cited by 13
Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text Mining
Gao, H., & Zhang, Z. (2015) · BioMed Research International · doi:10.1155/2015/615825 · Cited by 10
“Notably, KRAS-induced carcinogenesis can be inhibited when the interaction between RAS and the PI3K catalytic subunit P110α is blocked in vitro [20].”
BackgroundKras promotes myeloid differentiation through Wnt/β‐catenin signaling
Yokoyama, N., Kim, Y., Hirabayashi, Y., Tabe, Y., Takamori, K., Ogawa, H., & Iwabuchi, K. (2019) · FASEB BioAdvances · doi:10.1096/fba.2019-00004 · Cited by 10
Myocardial Cell Signaling During the Transition to Heart Failure
Zeglinski, M. R., Moghadam, A. R., Ande, S. R., Sheikholeslami, K., Mokarram, P., Sepehri, Z., Rokni, H., Mohtaram, N. K., Poorebrahim, M., Masoom, A., et al. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170053 · Cited by 13
Pesapane, A., Capasso, L., Sorbo, M. R. D., Scisciola, L., Troiani, T., Mele, D., Franzese, M., Puocci, A., Tortorella, G., Surina, S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07982-6 · Cited by 10
“Before enrolment, all participants gave written informed consent.”
Xing, Y., & Hogge, D. E. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.03.003 · Cited by 9
Vega-Cuesta, P., Ruiz‐Gómez, A., Molnar, C., Organista, M. F., Resnik-Docampo, M., Sanjuan, J. F., López‐Varea, A., & de Celis, J. F. (2020) · Developmental Biology · doi:10.1016/j.ydbio.2020.02.009 · Cited by 8
Aytenfisu, T. Y., Campbell, H. M., Chakrabarti, M., Amzel, L. M., & Gabelli, S. B. (2022) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-06566-8_1 · Cited by 17
Effects of constitutively active K-Ras on axon regeneration after optic nerve injury
Kiyota, N., Namekata, K., Nishijima, E., Guo, X., Kimura, A. K., Harada, C., Nakazawa, T., & Harada, T. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137124 · Cited by 12
pmTOR is a marker of aggressiveness in papillary thyroid carcinomas
Tavares, C., Coelho, M. J., Melo, M., da Rocha, A. G., Pestana, A., Batısta, R., Salgado, C., Eloy, C., Ferreira, L. B., Rios, E., et al. (2016) · Surgery · doi:10.1016/j.surg.2016.06.050 · Cited by 13
The rise of T-type channels in melanoma progression and chemotherapeutic resistance
Alza, L., Visa, A., Herreros, J., & Cantí, C. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188364 · Cited by 9
Increased osteoclastogenesis contributes to bone loss in the Costello syndrome Hras G12V mouse model
Nandi, S., Chennappan, S., Andrasch, Y., Fidan, M., Engler, M., Ahmad, M., Tuckermann, J. P., Zenker, M., & Cirstea, I. C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1000575 · Cited by 10
“Hras G12V mutations lead to its constitutive activation and subsequently to an enhanced activation of the MAPK and PI3K pathways (Castellano and Downward, 2011).”
BackgroundIdentification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer
Carter, R., Cheraghchi-Bashi, A., Westhorpe, A., Sheng, Y., Shanneik, Y., Elena, S., Ouaret, D., Yasuhiro, I., Catherine, K., Wilding, J., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0284 · Cited by 9
Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone
Bae, S., Mai, V.-H., Mun, S., Dong, D.-L., Han, K., Park, S., & Hyun, J. K. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13665 · Cited by 9
Liu, W., Hu, J., Wang, R., Han, Q., Liu, Y., & Wang, S. (2021) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000965 · Cited by 8
Signaling pathways as therapeutic targets in biliary tract cancer
Yang, J., Farren, M. R., Ahn, D. H., Bekaii‐Saab, T., & Lesinski, G. B. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1306055 · Cited by 8
Presence or Absence of Ras Dimerization Shows Distinct Kinetic Signature in Ras-Raf Interaction
Sarkar, S., & García, A. E. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.03.004 · Cited by 9
The Molecular Pathogenesis of Head and Neck Cancer
Hedberg, M. L., & Grandis, J. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00033-0 · Cited by 8
Gene expression profiling of giant fibroadenomas of the breast
Lee, J. P. Y., Thomas, A. J., Lum, S. K., Shamsudin, N. H., Hii, L., Mai, C., Wong, S. F., & Leong, C. (2021) · Surgical Oncology · doi:10.1016/j.suronc.2021.101536 · Cited by 13
Costamagna, A., Natalini, D., Leal, M. D. P. C., Simoni, M., Gozzelino, L., Cappello, P., Novelli, F., Ambrogio, C., Defilippi, P., Turco, E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.12.242 · Cited by 10
Geißert, R., Lammert, A., Wirth, S., Hönig, R., Lohfink, D., Unger, M., Pek, D., Schlüter, K., Scheftschik, T., Smit, D. J., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01484-2 · Cited by 8
“The importance of K-Ras-PI3-K signaling in various cellular processes, such as proliferation, apoptosis, differentiation, and tumorigenesis is generally accepted, although this seems to vary between cell types, tissues, and tumor entities (summarized in [48]).”
BackgroundGaravello, N. M., Pena, D. A., Bonatto, J. M. C., Duarte, M. L., Costa‐Junior, H. M., Schumacher, R. I., Forti, F. L., & Schechtman, D. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.10.021 · Cited by 8
Sethi, I., Cai, Z., Roberts, T. M., & Yuan, G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0588 · Cited by 8
“Consistent with our analysis, KRAS gain of function activations have previously been associated with resistance to pan PI3K inhibition [20] and switch from p110β to p110α dependence [21].”
Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines
Duerr, E., Mizukami, Y., Moriichi, K., Gala, M. K., Jo, W., Kikuchi, H., Xavier, R. J., & Chung, D. C. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00047.2011 · Cited by 8
“In its active, GTP-bound state, KRAS signals through multiple downstream 44 pathways including the RAF/MEK, MAPK, JNK and PI3-K pathways (4, 6, 21, 23), and 45 thereby regulates target genes that promote cell growth and survival.”
BackgroundModulation of Mosquito Immune Defenses as a Control Strategy
Rhodes, V. L. M., & Michel, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805350-8.00004-0 · Cited by 8
Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells
Xu, Y., Zong, S., Gao, X., Zhang, H., Wang, B., Li, P., Liu, T., & Li, S. (2018) · Gene · doi:10.1016/j.gene.2018.11.018 · Cited by 9
Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer
Lim, J. U., Negrao, M. V., & Hong, D. S. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-115849 · Cited by 9
Peptide inhibitors targeting Ras and Ras-associated protein–protein interactions
Han, D., Li, A., Zhu, L., Zhuang, C., Zhao, Q., & Zou, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116878 · Cited by 7
Strategizing the Development of Alzheimer’s Therapeutics
Davis, J. B., & Couch, R. D. (2014) · Advances in Alzheimer s Disease · doi:10.4236/aad.2014.33011 · Cited by 8
“…to TrkA stimulates a signal transduction cascade that promotes neuron survival through inhibition of apoptotic proteins via the PI- 3K/AKT pathway [158]-[160], through MEK/MAPK pathway stimulation of anti-apoptotic (pro-survival) proteins [161]-[163], and through upregulation of CREB [162] [163].”
BackgroundSignal Transduction Pathways in Ageing
Slack, C., & Tullet, J. M. A. (2018) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-2835-0_11 · Cited by 8
Wu, N., Huang, Y., Liu, F., Xu, X., Liu, B., & Wei, J. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-617 · Cited by 7
Rocco, A. D., Camero, S., Benedetti, A., Lozanoska‐Ochser, B., Megiorni, F., Marchese, C., Stramucci, L., Ciccarelli, C., Bouché, M., Bossi, G., et al. (2022) · Oncology Reports · doi:10.3892/or.2022.8363 · Cited by 7
ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation
Jia, D., Li, L., Wang, P., Feng, Q., Pan, X., Lin, P., Song, S., Yang, L., & Yang, J.-L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1043177 · Cited by 7
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
Cândido, M. F., Medeiros, M., Veronez, L. C., Bastos, D., Oliveira, K. L., Pezuk, J. A., Valera, E. T., & Brassesco, M. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020664 · Cited by 8
Kinetic Mechanism of Formation of Hyperactive Embryonic Ras in Cells
Wey, M., Lee, J., Kim, H. S., Jeong, S. S., Kim, J., & Heo, J. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b00902 · Cited by 8
Activation of Ras by Post-Translational Modifications
Xiang, S., Bai, W., Bepler, G., & Zhang, X. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00006-0 · Cited by 9
Promotion of invasion by mutant RAS is dependent on activation of the WASF3 metastasis promoter gene
Teng, Y., Ngoka, L. C. M., & Cowell, J. K. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22453 · Cited by 7
“One of the main consequences of RAS activation is the promotion of invasion and metastasis, although the underlying mechanism is poorly understood.(2) RAS activation leads to stimulation of the MAPK/ERK pathway leading to increased cell proliferation(3,4) as well as the PI3”
BackgroundInfluentialZhang, Z., Ma, M., Hu, R., Xu, B., Zong, L., Wei, H., & Meng, Y. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12926 · Cited by 7
Li, F., Zhang, C., & Fu, L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218839 · Cited by 8
Tang, J. H., & Chia, D. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v20.i5-6.90 · Cited by 8
Wang, X.-D., Nie, Q.-W., & Hu, M.-H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110647 · Cited by 6
“KRAS mutations in GTPase limit the hydrolyzation of GTP to GDP, and sustain the signaling activation, resulting in tumorigenesis and tumor progression (6, 7).”
Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma
Bhattacharya, S., & Rajpurohit, T. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220128161647 · Cited by 7
Uchida, S., Kojima, T., & Sugino, T. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610206 · Cited by 7
p52Shc regulates the sustainability of ERK activation in a RAF-independent manner
Yoshizawa, R., Umeki, N., Yamamoto, A., Okada, M., Murata, M., & Sako, Y. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-01-0007 · Cited by 7
Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance
Río-Vilariño, A., del Puerto‐Nevado, L., García‐Foncillas, J., & Cebrián, A. (2021) · Cancers · doi:10.3390/cancers13153757 · Cited by 6
“The constitutively active state of these proteins promotes RAS binding to BRAF leading to overactivation of several signalling pathways implicated in cell proliferation, including PI3K/AKT, MEK, and ERK pathways [49,84] and, more recently documented, Wnt/β-catenin pathway [85].”
Background
Metadata
- Authors
- Castellano, E., & Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 261-274
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3128635
- OpenAlex
- W2047401805
- Cited by
- 762
- References
- 206
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.